Compare AbbVie Inc (ABBV) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Costco Wholesale Corporation — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Costco Wholesale Corporation trades at $942.95 (market cap $422.52B). The key difference: AbbVie Inc and Costco Wholesale Corporation are close in size by market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | COST | |
|---|---|---|
Market Cap | $438.19B | $422.52B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $1.09K |
52-Week Low | $197.38 | $849.63 |
Enterprise Value | $502.45B | $410.66B |
Dividend Yield | 2.79% | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Costco (COST) trades at $952.75, up 0.52% with neutral technical signals. The company shows steady revenue growth, reaching $275.24B in 2025, and maintains strong profitability with a 3.01% net margin. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Analyst sentiment remains bullish with 65.52% buy ratings and a $1,120 consensus price target, while institutional buying activity continues.
Costco's outlook is positive due to membership fee growth and expansion, though high valuation multiples (P/E 47.93) pose risks. Key opportunities include consistent cash flow generation and market share gains, while risks involve competitive pressures and economic sensitivity. The stock offers long-term growth potential but requires monitoring of valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
